A Phase 1 dose escalation, safety, and pharmacokinetic study of PF-06650808, an anti-Notch3 antibody drug conjugate, in adult patients with advanced solid tumors

被引：4
|
作者：
Rosen, L. S. [1 ]
Wesolowski, R. [2 ]
Gibson, B. [3 ]
Baffa, R. [3 ]
Liao, K. H. [3 ]
Masters, J. [3 ]
Hua, S. Y. [3 ]
Deng, S. [3 ]
Shazer, R. [3 ]
Tolcher, A. W. [4 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol & Oncol, Med Ctr,Dept Med 9, Los Angeles, CA 90095 USA
[2] Ohio State Univ, Ctr Comprehens Canc, Breast Canc Res Program, Columbus, OH 43210 USA
[3] Pfizer Inc, Biotechnol Clin Dev, La Jolla, CA USA
[4] South Texas Accelerated Res Therapeut, Clin Res, San Antonio, TX USA
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)31948-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
30LBA
引用
收藏
页码：S725 / S725
页数：1
相关论文
共 50 条
  • [31] First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors
    Garrido-Laguna, Ignacio
    Krop, Ian
    Burris, Howard A., III
    Hamilton, Erika
    Braiteh, Fadi
    Weise, Amy M.
    Abu-Khalaf, Maysa
    Werner, Theresa L.
    Pirie-Shepherd, Steven
    Zopf, Christopher J.
    Lakshminarayanan, Mani
    Holland, Jaymes S.
    Baffa, Raffaele
    Hong, David S.
    INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (07) : 1798 - 1808
  • [32] Phase 1 Dose-Escalation Study of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor α-Targeting Antibody-Drug Conjugate, in Patients With Solid Tumors
    Moore, Kathleen N.
    Borghaei, Hossein
    O'Malley, David M.
    Jeong, Woondong
    Seward, Shelly M.
    Bauer, Todd M.
    Perez, Raymond P.
    Matulonis, Ursula A.
    Running, Kelli L.
    Zhang, Xiaoyan
    Ponte, Jose F.
    Ruiz-Soto, Rodrigo
    Birrer, Michael J.
    CANCER, 2017, 123 (16) : 3080 - 3087
  • [33] A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors
    Naing, Aung
    Gainor, Justin F.
    Gelderblom, Hans
    Forde, Patrick M.
    Butler, Marcus O.
    Lin, Chia-Chi
    Sharma, Sunil
    de Olza, Maria Ochoa
    Varga, Andrea
    Taylor, Matthew
    Schellens, Jan H. M.
    Wu, Hongqian
    Sun, Haiying
    Silva, Antonio P.
    Faris, Jason
    Mataraza, Jennifer
    Cameron, Scott
    Bauer, Todd M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [34] A Phase 1 study of the anti-tissue factor antibody-drug conjugate XB002 in patients with advanced solid tumors (JEWEL-101): initial results from the dose-escalation stage
    Ulahannan, S.
    Johnson, M. L.
    Park, H.
    Vandross, A.
    Uttamsingh, S.
    Li, J.
    Syed, M.
    Tolcher, A.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S92 - S93
  • [35] Phase 1 Pharmacokinetic and Drug-Interaction Study of Dasatinib in Patients With Advanced Solid Tumors
    Johnson, Faye M.
    Agrawal, Shruti
    Burris, Howard
    Rosen, Lee
    Dhillon, Navneet
    Hong, David
    Blackwood-Chirchir, Anne
    Luo, Feng R.
    Sy, Oumar
    Kaul, Sanjeev
    Chiappori, Alberto A.
    CANCER, 2010, 116 (06) : 1582 - 1591
  • [36] A phase 1, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors.
    Shapiro, Geoffrey
    Mier, James Walter
    Hilton, John Frederick
    Gandhi, Leena
    Chau, Nicole G.
    Bullock, Andrea J.
    Supko, Jeffrey G.
    Verselis, Sigitas Jonas
    Murgo, Kayla
    Sze, Cameron
    Gotthardt, Susan
    Wolanski, Andrew
    Alexander, W. James
    Kumar, Ashok
    Holden, Sylvia Adell
    Chafai-Fadela, Karima
    Ram, Siya
    Menon, Krishna E.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] Phase I, dose-escalation study of BIIB022 (anti-IGF-1R antibody) in advanced solid tumors
    von Mehren, M.
    Britten, C.
    Lear, K.
    Camidge, D. R.
    Wainberg, Z. A.
    Pieslor, P. C.
    Darif, M.
    Harris, S.
    Balogh, K.
    Leong, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors
    Hassan, Raffit
    Blumenschein, George R., Jr.
    Moore, Kathleen N.
    Santin, Alessandro D.
    Kindler, Hedy L.
    Nemunaitis, John J.
    Seward, Shelly M.
    Thomas, Anish
    Kim, Stella K.
    Rajagopalan, Prabhu
    Walter, Annette O.
    Laurent, Dirk
    Childs, Barrett H.
    Sarapa, Nenad
    Elbi, Cem
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (16) : 1824 - +
  • [39] Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial
    Patnaik, Amita
    Weiss, Glen J.
    Rasco, Drew W.
    Blaydorn, Lisa
    Mirabella, Amy
    Beeram, Murali
    Guo, Wei
    Lu, Sharon
    Danaee, Hadi
    McEachern, Kristen
    Im, Ellie
    Sachdev, Jasgit C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (01) : 93 - 103
  • [40] A dose escalation and pharmacokinetic study of the biweekly administration of paclitaxel, gemcitabine and oxaliplatin in patients with advanced solid tumors
    Zacharenia Saridaki
    Periklis Pappas
    John Souglakos
    Martha Nikolaidou
    Nikolaos Vardakis
    Athanasios Kotsakis
    Marios Marselos
    Vassilis Georgoulias
    Dimitris Mavroudis
    Cancer Chemotherapy and Pharmacology, 2009, 65 : 121 - 128
12345